Search - tctmd.com

Displaying 1 - 20 of 124

Sort: Relevancy | Date

News Conference News ISC 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

Todd Neale

February 09, 2026

News Daily News

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Michael O'Riordan

January 30, 2026

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Andexanet Alfa Pulled From US Market

Todd Neale

December 22, 2025

News Daily News

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Michael O'Riordan

November 24, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

L.A. McKeown

May 16, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Daily News

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Michael O'Riordan

March 03, 2025

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

L.A. McKeown

February 14, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

Shelley Wood

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

Caitlin E. Cox

September 03, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

L.A. McKeown

August 26, 2024

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

L.A. McKeown

August 19, 2024

Advertisement

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Andexanet Alfa Pulled From US Market

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

TCTMD’s Top 10 Most Popular Stories for August 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Scientific Statement Reviews Current Antithrombotic Options in PAD

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content